Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRO-NAFLD-OLE: Extension Study of Resmetirom in NAFLD
NCT04951219Phase 3Active, not recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of resmetirom in non-alcoholic fatty liver disease (NAFLD) (6 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Incidence of adverse events at 52 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
resmetirom
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04951219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951219.